Array BioPharma: Cancer drug showing favorable results in phase 3 trials
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of results from the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI (encorafenib), a BRAF... Read More
Monday July 8, 2019 0 comments
Array BioPharma to be acquired by drug giant Pfizer for $11.4B
BOULDER -- Drug manufacturing giantPfizer and Array BioPharma today announced they have entered into a definitive merger agreement under which Pfizer will acquire Array, a Boulder-based... Read More
Monday June 17, 2019 0 comments
Array BioPharma drugs recommended by National Comprehensive Cancer Network for CR care
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the National Comprehensive Cancer Network(NCCN) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to... Read More
Tuesday March 19, 2019 0 comments
Array BioPharma announces positive results for cancer drug combo
BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC... Read More
Tuesday January 15, 2019 0 comments
European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment
BOULDER -- Array BioPharma Inc . (NASDAQ: ARRY) today announced the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of... Read More
Friday September 21, 2018 0 comments
Array BioPharma names Carrie S. Cox chair of its board of directors
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More
Tuesday August 14, 2018 0 comments
Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More
Tuesday August 7, 2018 0 comments
Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More
Monday July 30, 2018 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
